Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » .11 and Up! » ProtoKinetix Takes Delivery of GMP AAGP(R) PKX-001 Dedicated for Phase 1 Trial

 - UBBFriend: Email this page to someone!    
Author Topic: ProtoKinetix Takes Delivery of GMP AAGP(R) PKX-001 Dedicated for Phase 1 Trial
jackbequick
Member


Rate Member
Icon 1 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
ProtoKinetix Takes Delivery of GMP AAGP(R) PKX-001 Dedicated for Phase 1 Trial
8:30 AM ET 1/24/20 | BusinessWire

MARIETTA, Ohio--(BUSINESS WIRE)--January 24, 2020--

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001 (AAGP(R)) molecule. We are shipping sufficient molecule to Iotron Industries in British Columbia for sterilization. The sterilization process is a 1-week turnaround. After sterilization there will be one more process needed that will take up to 3-weeks for quality assurance. The sterilized molecule will then be sent to the University of Alberta for use in the continuation of the Phase-1 first-in-human clinical trials of PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type-1 diabetes. We are shipping ample molecule to include another 10-patients in the clinical trials. This represents the most significant scale-up of manufacturing in the Company's history. Upon receipt of the molecule, request for approval of the amendments will be submitted to Health Canada by the sponsor, the University of Alberta. This total process will take 4-6 weeks.

The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.

Dr. James Shapiro Bio

Dr. James Shapiro Video

About the Edmonton Protocol

PKX-001 is the designation given to the lead drug product molecule of the AAGP(R) family. Islet cell transplants are well recognized as a viable and effective treatment for Type-1 diabetes. The PKX-001 study will treat islet cells prior to transplantation into human test subjects. The clinical trials primary objective is the establishment of patient safety. The study will also be making observations related to indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells. The trial follows extensive preclinical evaluation in experimental models (to learn more, refer to this link: Diabetes).

To obtain additional information and updates regarding this trial please use the following link: Clinicaltrials.gov - Islet Transplantation Using PKX-001.

Posts: 193 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share